I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original |
Terms/Details (Date) |
Chemokine |
Pharmaceutical Product Development Inc. |
Chemokine re-acquired rights to the white-blood-cell mobilizer CTCE-0214; rights were granted to PPD in 2003 |
PPD will get $0.1M up front and up to $2.5M in milestone payments; Chemokine also will pay about $1.7M to buy back preferred shares held by PPD (4/17) |
ImClone |
Merck KGaA (Germany) |
An arbitrator ruled in favor of ImClone in a dispute over rights to the IgG1 monoclonal antibody IMC-11F8 |
The binding ruling leaves ImClone with exclusive rights to the epidermal growth factor receptor antibody outside the U.S. and Canada (4/4) |
Immunicon |
Pfizer Inc. |
They expanded deal focused on developing reagents to detect certain antigens on circulating tumor cells |
The deal, begun in February 2003, was amended to permit the companies to initiate new clinical research studies (3/28) |
Memory |
F. Hoffmann- La Roche Ltd. (Switzerland) |
The companies ended the discovery portion of their collaborations on PDE4 inhibitors |
Memory's co-promotion rights to MEM 1414 and MEM 1917 were expanded to include Europe; funding under the deal will be redirected to their nicotinic alpha-7 collaboration (2/28) |
II. TERMINATED AGREEMENTS | |||
Nastech |
Merck & Co. Inc. |
Merck ended their deal to develop PYY3- 6 nasal spray for obesity |
Merck made the move following review of data from a proof-of- oncept study; Nastech intends to continue the program, with a dosing study followed by a Phase II trial (3/2) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
TSE = Toronto Stock Exchange. | |||
